Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Reexamination Certificate
2005-07-26
2005-07-26
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
C424S208100, C530S351000
Reexamination Certificate
active
06921530
ABSTRACT:
Low doses of IL-2 are administered to potentiate an immune response after antiviral treatment. IL-2 is also administered in conjunction with immunotherapy to enhance the immune response to infection.
REFERENCES:
patent: 4933433 (1990-06-01), Tamblyn
patent: 4938956 (1990-07-01), Howard
patent: 4940456 (1990-07-01), Sibalis
patent: 5126129 (1992-06-01), Wiltrout
patent: 5420109 (1995-05-01), Suto
patent: 6045788 (2000-04-01), Smith
patent: 6190656 (2001-02-01), Lane et al.
patent: 6509313 (2003-01-01), Smith
patent: WO 97/31622 (1997-04-01), None
patent: WO 97/41831 (1997-11-01), None
Kakumu, S., et al., 1988, “Pilot study of recombinant human interleukin 2 for chronic type B hepatitis”, Hepatol. 8(3):487-492.
Tilg, H., et al., 1993, “Pilot study of natural human interleukin-2 in patients with chronic hepatitis B: Immunomodulatory and antiviral effects”, J. Hepatol. 19:259-267.
Pardo, M., et al., 1997, “A pilot study of recombinant interleukin-2 for treatment of chronic hepatitis C”, Hepatol. 26(5):1318-1321.
Newman, M. J., and M. F. Powell, 1995, “Immunological and formulation design considerations for subunit vaccines”, in Vaccin Design: The Subunit and Adjuvant Approach, Powell, M. F., and M. J. Newman, eds., Plenum Press, New York, pp. 1-42.
Gursel, M., et al., 1998, “The immunological co-adjuvant action of liposomal interleukin-2: the role of mode of localisation of the cytokine and antigen in the vesicles”, J. Drug Target. 5(2):93-98.
Barouch, D. H., et al., 1998, “Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/lg administration”, J. Immunol. 161(4):1875-82.
Vandamme, A. M., et al., 1998, “Anti-human immunodeficiency virus drug combination strategies”, Antivir. Chem. Chemo. 9:187-203.
Tilg, H., et al., 1993, “Pilot study of natural human interleukin-2 in patients with chronic hepatitis B”, J. Hepatol. 19:259-267.
Tsai, S. L., and S. N. Huang, 1997, “T cell mechanisms in the immunopathogenesis of viral hepatitis B and C”, J. Gastroenterol. Hepatol. 12 (Suppl.):S227-S235.
Caligiuri, Selective Modulation of Human Natural Killer Cells In Vivo After Prolonged Infusion of Low Dose Recombinant Interleukin 2, Journal of Clinical Investigation, 1993, p. 123-132.
Teppler, Efficacy of Low Doses of the Polyethylene Glycol Derivative of Interleukin-2 in Modulating the Immune Response of Patients with Human Immunodeficiency Virus Type 1 Infection, Journal of Infectious Diseases, 1993; 167:291-298.
Anderson, Effects of Route and Formulation on Clinical Pharmacokinetics of Interleukin-2, Clinical Pharmacokinetics, 1994, 27; 1:19-31.
Yamamoto, Hepatic Arterial Infusion of Interleukin-2 in Advanced Hepatocellular Carcinoma, Acta Oncologica, 1993, 32; 1:43-51.
Jacobson, Rational Interleukin 2 Therapy for HIV Positive Individuals: Daily Low Doses Enhance Immune Function Without Toxicity, Proceedings of the National Academy of Sciences of the United States of America, 1996, 93:10405-10410.
Meuer, Low Dose Interleukin-2 Induces Systemic Immune Responses Against HBsAg In Immunodefecient Non-Responders to Hepatitis B Vaccination, The Lancet, 1989, No. 8628, 00. 15-18.
Bernstein, Prolonged Administration of Low-Dose Interleukin-2 in Human Immunodeficiency Virus-Associated Malignancy Results in Selective Expansion of Innate Immune Effectors Without Significant Clinical Toxicity, Blood, 1995, 86; 9:3287-3294.
Lechman, et al., Hepatology, 1996, 24:790-795.
Missale, et al., J.Clin.Invest., 1996, 98:706-714.
Caligiuri, et al., Journal of Clinical Oncology, 1991, 9:2110-2119.
Rehermann, et al., J.Clin.Invest., 1996, 98:1432-1440.
Hiroishi, et al., Hepatology, 1997, 25:705-712.
Koziel, et al., J.Clin.Invest., 1995, 96:2311-2321.
Guidotti, et al., Proc. Natl. Acad. Sci. USA, 1994, 91:3764-3768.
Tsui, et la., Proc. Natl. Acad. Sci. USA, 1995, 92:12398-12402.
Guidotti, et al., Immunity, 1996, 4:25-36.
Tilg, et al., Journal of Heptalogy, 1993, 10:259-267.
Artillo, et al., Journal of Medical Virology, 1998, 54:167-172.
Pardo, et al., Hepatology, 1997, 26:1318-1321.
Schlaak, et al., Hepatology, AASLD Abstracts, 1998, 28:1380.
Uberti-Foppa, et al., Hepatology, AASLD Abstracts, 1998, 28:1249.
Cornell Research Foundation Inc.
Darby & Darby
Parkin Jeffrey S.
LandOfFree
Low dose IL-2 for potentiation of immunity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Low dose IL-2 for potentiation of immunity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Low dose IL-2 for potentiation of immunity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3403944